Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human umbilical cord blood-derived mesenchymal stem cells
- Development stage
- Unknown
- Lead developer
- Medipost
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Inhalation
01
Overview
PNEUMOSTEM (human umbilical cord blood-derived mesenchymal stem cells) is an allogeneic, off-the-shelf cell therapy developed by Medipost for the prevention and treatment of bronchopulmonary dysplasia (BPD) in premature infants. The product consists of ex vivo cultured mesenchymal stem cells (MSCs) derived from unrelated human umbilical cord blood. These cells are administered via a single intratracheal dose and exert their therapeutic effects through paracrine mechanisms that reduce lung inflammation, fibrosis, and apoptosis. Additionally, hUCB-MSCs have the potential to differentiate into pulmonary epithelial and endothelial cells, thereby supporting the regeneration of damaged lung tissue. The therapy has received Orphan Drug and Fast Track designations from the US FDA and Orphan Drug designation from the EMA.
- Brand names
- PNEUMOSTEM
- Other names
- hUCB-MSCsallogeneic human umbilical cord blood-derived mesenchymal stem cells
Beyond the preview
Go deeper on human umbilical cord blood-derived mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human umbilical cord blood-derived mesenchymal stem cells.